SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Apricus Biosciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: OldBoar who wrote (1891)4/28/2016 10:03:25 PM
From: phoenix_rising  Read Replies (2) of 2026
 
Takeda paid $1.6m for Uk rights. Clearly they expected much better sales than they have achieved if they have just given up the rights back to the company. One of the issues has been that the NHS has not approved payment for Vitaros in many regions, so it is only available privately from what I researched a year or so ago.

The Takeda agreement was tiered double digit, so this new deal with Ferring at high single digit and possibly into double digit is a bit shit unless Ferring can really get sales moving.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News